Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

74 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Palpation thyroiditis seen on F-18 FDG PET/CT.
Blazak JK, Ravi Kumar AS. Blazak JK, et al. Clin Nucl Med. 2011 Mar;36(3):261-3. doi: 10.1097/RLU.0b013e3181f9e038. Clin Nucl Med. 2011. PMID: 21285697
FDG PET in follicular lymphoma: more than a staging test?
Ravi Kumar AS, Tam C, Hofman MS. Ravi Kumar AS, et al. Leuk Lymphoma. 2017 Jul;58(7):1521-1523. doi: 10.1080/10428194.2016.1272691. Epub 2017 Jan 16. Leuk Lymphoma. 2017. PMID: 28092995 No abstract available.
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study.
Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, Iravani A, Kong G, Ravi Kumar A, Murphy DG, Eu P, Jackson P, Scalzo M, Williams SG, Sandhu S. Hofman MS, et al. Among authors: ravi kumar a. Lancet Oncol. 2018 Jun;19(6):825-833. doi: 10.1016/S1470-2045(18)30198-0. Epub 2018 May 8. Lancet Oncol. 2018. PMID: 29752180 Clinical Trial.
Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series.
Goncalves I, Burbury K, Michael M, Iravani A, Ravi Kumar AS, Akhurst T, Tiong IS, Blombery P, Hofman MS, Westerman D, Hicks RJ, Kong G. Goncalves I, et al. Among authors: ravi kumar as. Eur J Nucl Med Mol Imaging. 2019 Aug;46(9):1902-1910. doi: 10.1007/s00259-019-04389-2. Epub 2019 Jun 11. Eur J Nucl Med Mol Imaging. 2019. PMID: 31187162
Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy.
Thang SP, Violet J, Sandhu S, Iravani A, Akhurst T, Kong G, Ravi Kumar A, Murphy DG, Williams SG, Hicks RJ, Hofman MS. Thang SP, et al. Among authors: ravi kumar a. Eur Urol Oncol. 2019 Nov;2(6):670-676. doi: 10.1016/j.euo.2018.11.007. Epub 2018 Dec 13. Eur Urol Oncol. 2019. PMID: 31412006 Clinical Trial.
74 results